GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped? A Critical Analysis

GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped? A Critical Analysis Please like and subscribe if you enjoyed this video :-)    Abstract The treatment landscape for managing weight in non-diabetic patients has changed dramatically with the introduction of

Semaglutide Use Shows Bonus Benefit Of Osteoarthritis Risk Reduction

Semaglutide Use Shows Bonus Benefit Of Osteoarthritis Risk Reduction Overview Osteoarthritis (OA) is a widespread degenerative joint condition. While the influence of obesity on OA is well-established, the effect of semaglutide on OA remains less understood.   The objective was to evaluate the effect of semaglutide on the risk of OA among patients with

GLP-1 Agonists for Obesity in Non-Diabetic Patients: Game Changer or Overhyped? A Critical Analysis